SCHEMBL2212151

SCHEMBL2212151

CSc1nc(-c2ccc(-c3ccccc3)nc2)cc2ccnn12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.36
POLB P06746 3/20 0.36
ADORA2A P29274 1/20 0.35
ADORA1 P30542 1/20 0.35
SMN1; SMN2 Q16637 5/20 0.35
NPC1 O15118 3/20 0.35
LMNA P02545 3/20 0.35
RAB9A P51151 3/20 0.35
MAPT P10636 2/20 0.35
CDK2 P24941 2/20 0.35
DHODH Q02127 1/20 0.35
CCNE1 P24864 1/20 0.35
LDHA P00338 1/20 0.35
HPGDS O60760 1/20 0.35
CHEK1 O14757 1/20 0.34
CCNA2 P20248 1/20 0.34
CCNA1 P78396 1/20 0.34
ALDH1A1 P00352 4/20 0.34
TDP1 Q9NUW8 2/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2212035 0.90 SMN1; SMN2 (0.39) GSK3BPOLBADORA2AADORA1SMN1; SMN2
SCHEMBL2216151 0.82 CYP2A6 (0.34) SMN1; SMN2NPC1RAB9AMAPTMEN1
SCHEMBL2212656 0.82 SMN1; SMN2 (0.35) GSK3BPOLBADORA2AADORA1SMN1; SMN2
SCHEMBL2211402 0.80 BPTF (0.37) GSK3BPOLBSMN1; SMN2LMNARAB9A
SCHEMBL2213284 0.79 NPC1 (0.38) GSK3BSMN1; SMN2NPC1LMNARAB9A
SCHEMBL2215466 0.76 MAPT (0.41) ADORA1SMN1; SMN2NPC1LMNARAB9A
SCHEMBL2216178 0.76 DHODH (0.43) POLBSMN1; SMN2NPC1LMNARAB9A
SCHEMBL2213701 0.76 CDK2 (0.44) POLBSMN1; SMN2NPC1RAB9AMAPT
SCHEMBL2213882 0.76 SMN1; SMN2 (0.45) SMN1; SMN2NPC1LMNARAB9AMAPT
SCHEMBL2213852 0.74 ALOX5 (0.44) POLBSMN1; SMN2NPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797096-B1 PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) BAYER SCHERING PHARMA AG (DE) 2011-07-27 EP disclosed
US-7745446-B2 Pyrazolo[1,5-c]pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-29 US disclosed
US-20070254046-A1 Novel Pyrazolopyrimidines ALTANA PHARMA AG (DE) 2007-11-01 US disclosed
EP-1797096-A2 NOVEL PYRAZOLOPYRIMIDINES Altana Pharma AG (DE) 2007-06-20 EP disclosed
WO-2006027346-A2 NOVEL PYRAZOLOPYRIMIDINES ALTANA PHARMA AG (DE) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254046-A1 Novel Pyrazolopyrimidines MCL1, RARS2, CDK4 GSK3B 4248/4885POLB 828/4885ADORA2A 3513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.